Biopharmaceutical Industry Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product Type, By Therapeutic Application, By Region & Competition, 2020-2030F
바이오의약품 세계 시장 규모는 2024년 4,358억 2,000만 달러로 평가되었고, 2030년까지 8.25%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 큰 성장이 예상됩니다.
세계 바이오의약품 시장은 제약 및 헬스케어 산업에서 가장 역동적이고 빠르게 발전하고 있는 분야입니다. 이 시장은 생물, 세포, 단백질과 같은 생물학적 자원에서 유래한 의약품 및 치료법인 바이오의약품의 개발, 생산 및 상업화를 포괄합니다. 이러한 제품들은 다양한 질병과 질환에 대해 고도로 표적화된 효과적인 치료법을 제공하는 헬스케어의 중요한 발전입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
4,358억 2,200만 달러 |
| 시장 규모 : 2030년 |
6,956억 9,000만 달러 |
| CAGR : 2025-2030년 |
8.25% |
| 급성장 부문 |
단일클론항체 |
| 최대 시장 |
북미 |
세계 바이오의약품 시장은 지난 몇 년간 지속적인 성장세를 보이고 있습니다. 이러한 성장의 원동력은 세계 인구의 고령화, 만성질환 증가, 의료비 지출 증가, 혁신적인 바이오의약품의 지속적인 도입 등 다양한 요인에 기인합니다. 시장의 회복력은 경기 침체기에도 불구하고 제약기업과 투자자들에게 매력적인 투자 기회로 작용하고 있습니다.
시장 성장 촉진요인
연구개발 혁신
주요 시장 이슈
규제 장벽과 컴플라이언스 복잡성
주요 시장 동향
생명공학의 발전과 개인 맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 제품 유형별(단클론항체, 재조합 성장인자, 정제 단백질, 재조합 단백질, 재조합 호르몬, 백신, 재조합 효소, 세포 및 유전자 치료, 합성 면역 조절제, 기타)
- 치료 용도별(종양학, 염증성 및 감염증, 자가면역 질환, 대사 질환, 호르몬 질환, 심혈관 질환, 신경 질환, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 바이오의약품 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 바이오의약품 시장 : SWOT 분석
제14장 경쟁 구도
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Johnson & Johnson
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche AG
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Biopharmaceutical Industry Market was valued at USD 435.82 billion in 2024 and is anticipated to project significant growth in the forecast period with a CAGR of 8.25% through 2030. The Global Biopharmaceutical Industry Market is a dynamic and rapidly evolving sector within the broader pharmaceutical and healthcare industry. It encompasses the development, production, and commercialization of biopharmaceutical products, which are medicinal drugs and therapies derived from biological sources such as living organisms, cells, or proteins. These products represent a significant advancement in healthcare, offering highly targeted and effective treatments for a wide range of diseases and medical conditions.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 435.82 Billion |
| Market Size 2030 | USD 695.69 Billion |
| CAGR 2025-2030 | 8.25% |
| Fastest Growing Segment | Monoclonal Antibodies |
| Largest Market | North America |
The global biopharmaceutical market has been on a consistent growth trajectory for several years. This growth is driven by factors such as an aging global population, increasing prevalence of chronic diseases, rising healthcare expenditures, and the continuous introduction of innovative biopharmaceutical products. The market has demonstrated resilience even in the face of economic downturns, making it an attractive investment opportunity for pharmaceutical companies and investors.
Key Market Drivers
Research and Development Innovations
Research and development (R&D) innovations are at the heart of the biopharmaceutical industry. They are essential for the creation of novel therapies, drugs, and treatments. The importance of R&D innovations can be attributed to several factors. For instance, in February 2025, Zydus Lifesciences launched VaxiFlu-4, India's first quadrivalent influenza vaccine, representing a major advancement in vaccine technology. Developed at Zydus's Vaccine Technology Centre in Ahmedabad, it is formulated based on WHO recommendations to protect against emerging influenza virus strains.
With technological breakthroughs such as CRISPR-Cas9 gene editing, next-generation sequencing, and artificial intelligence, scientists can delve deeper into the understanding of diseases and develop innovative solutions. R&D innovations enable biopharmaceutical companies to tackle previously untreatable diseases and medical conditions, addressing unmet healthcare needs. Companies that invest heavily in R&D gain a competitive edge by bringing groundbreaking therapies to market, which can lead to substantial profits and market dominance. Continuous R&D ensures a pipeline of new drugs and therapies, fostering long-term sustainability for the biopharmaceutical industry.
Key Market Challenges
Regulatory Hurdles and Compliance Complexity
The biopharmaceutical industry operates in a highly regulated environment due to the critical nature of healthcare products. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous standards and requirements on the development, testing, and manufacturing of biopharmaceutical products. Meeting these regulatory standards can be a time-consuming and costly process. Companies must invest substantial resources in conducting clinical trials, documenting safety and efficacy data, and ensuring compliance with evolving regulations. Moreover, the variability in regulatory requirements across different countries and regions can pose a significant challenge for global market expansion. Additionally, as biopharmaceutical research advances into newer areas such as gene therapies and cell-based treatments, regulators are often grappling with the development of appropriate guidelines, which can further slowdown product approvals.
Key Market Trends
Biotechnology Advancements and Personalized Medicine
One of the most significant trends in the biopharmaceutical industry is the rapid advancement of biotechnology, particularly in areas like genomics, proteomics, and bioinformatics. These advancements are enabling the development of highly targeted and personalized medicines. Rather than taking a one-size-fits-all approach, biopharmaceutical companies are increasingly tailoring treatments to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. This trend is transforming the treatment landscape, allowing for more effective therapies with fewer side effects. Personalized medicine not only improves patient outcomes but also reduces healthcare costs by minimizing ineffective treatments and adverse reactions. Biopharmaceutical companies are investing heavily in research to identify biomarkers, develop companion diagnostics, and create therapies that precisely match a patient's genetic profile.
Key Market Players
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Johnson & Johnson
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche AG
Report Scope:
In this report, the Global Biopharmaceutical Industry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Biopharmaceutical Industry Market, By Product Type:
- Monoclonal Antibodies
- Recombinant Growth Factors
- Purified Proteins
- Recombinant Proteins
- Recombinant Hormones
- Vaccines
- Recombinant Enzymes
- Cell and Gene Therapies
- Synthetic Immunomodulators
- Others
Biopharmaceutical Industry Market, By Therapeutic Application:
- Oncology
- Inflammatory and Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- Cardiovascular Diseases
- Neurological Diseases
- Other
Biopharmaceutical Industry Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Industry Market.
Available Customizations:
Global Biopharmaceutical Industry market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Biopharmaceutical Industry Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators, Others)
- 5.2.2. By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, Other)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Market Map
6. North America Biopharmaceutical Industry Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Therapeutic Application
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Biopharmaceutical Industry Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product Type
- 6.3.1.2.2. By Therapeutic Application
- 6.3.2. Canada Biopharmaceutical Industry Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product Type
- 6.3.2.2.2. By Therapeutic Application
- 6.3.3. Mexico Biopharmaceutical Industry Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product Type
- 6.3.3.2.2. By Therapeutic Application
7. Europe Biopharmaceutical Industry Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Therapeutic Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Biopharmaceutical Industry Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product Type
- 7.3.1.2.2. By Therapeutic Application
- 7.3.2. United Kingdom Biopharmaceutical Industry Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product Type
- 7.3.2.2.2. By Therapeutic Application
- 7.3.3. Italy Biopharmaceutical Industry Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecasty
- 7.3.3.2.1. By Product Type
- 7.3.3.2.2. By Therapeutic Application
- 7.3.4. France Biopharmaceutical Industry Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product Type
- 7.3.4.2.2. By Therapeutic Application
- 7.3.5. Spain Biopharmaceutical Industry Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product Type
- 7.3.5.2.2. By Therapeutic Application
8. Asia-Pacific Biopharmaceutical Industry Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Therapeutic Application
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Biopharmaceutical Industry Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product Type
- 8.3.1.2.2. By Therapeutic Application
- 8.3.2. India Biopharmaceutical Industry Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product Type
- 8.3.2.2.2. By Therapeutic Application
- 8.3.3. Japan Biopharmaceutical Industry Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product Type
- 8.3.3.2.2. By Therapeutic Application
- 8.3.4. South Korea Biopharmaceutical Industry Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product Type
- 8.3.4.2.2. By Therapeutic Application
- 8.3.5. Australia Biopharmaceutical Industry Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product Type
- 8.3.5.2.2. By Therapeutic Application
9. South America Biopharmaceutical Industry Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Therapeutic Application
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Biopharmaceutical Industry Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product Type
- 9.3.1.2.2. By Therapeutic Application
- 9.3.2. Argentina Biopharmaceutical Industry Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product Type
- 9.3.2.2.2. By Therapeutic Application
- 9.3.3. Colombia Biopharmaceutical Industry Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product Type
- 9.3.3.2.2. By Therapeutic Application
10. Middle East and Africa Biopharmaceutical Industry Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Therapeutic Application
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Biopharmaceutical Industry Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product Type
- 10.3.1.2.2. By Therapeutic Application
- 10.3.2. Saudi Arabia Biopharmaceutical Industry Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product Type
- 10.3.2.2.2. By Therapeutic Application
- 10.3.3. UAE Biopharmaceutical Industry Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product Type
- 10.3.3.2.2. By Therapeutic Application
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Biopharmaceutical Industry Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Abbvie Inc.
- 14.2. Amgen Inc.
- 14.3. Bristol-Myers Squibb Company
- 14.4. Eli Lilly and Company
- 14.5. Johnson & Johnson
- 14.6. Novartis AG
- 14.7. Novo Nordisk AS
- 14.8. Pfizer Inc.
- 14.9. GlaxoSmithKline PLC
- 14.10. F. Hoffmann-La Roche AG
15. Strategic Recommendations
16. About Us & Disclaimer
